CELL INTELLIGENCE · 肿瘤细胞治疗研究

胶质瘤免疫监视与免疫治疗应答交汇处的脑屏障

Brain barriers at the crossroads of glioma immune surveillance and immunotherapy response.

FECH：影响 CAR-T 细胞表型与功能的新型代谢靶点

FECH, a novel metabolic target influencing CAR T-cell phenotype and function.

围手术期髓系细胞重塑塑造胶质母细胞瘤中 CAR-T 细胞的疗效

Perioperative myeloid cell remodeling shapes CAR-T cell efficacy in glioblastoma.

当前的临床前模型是否足以评估 CAR-T 细胞疗法在儿童高级别胶质瘤中的作用？

Are the current preclinical models adequate to evaluate CAR-T cell therapy in pediatric high-grade gliomas?

靶向 PDPN 与 GD2 的新型 CAR-T 细胞组合以克服胶质母细胞瘤异质性

Novel CAR T cell blend targeting PDPN and GD2 to overcome glioblastoma heterogeneity.

这种新型 PDPN/GD2 CAR-T 细胞混合物在晚期临床前胶质母细胞瘤模型中显示出强效疗效，提示其具有治疗异质性胶质母细胞瘤和解决单抗原 CAR-T 细胞疗法相关局限性的潜力。

铁死亡武装的树突状细胞疫苗用于胶质瘤免疫治疗

Ferroptosis-armed dendritic cell vaccines for glioma immunotherapy.

不同的肿瘤免疫微环境格局驱动胶质母细胞瘤中分化的免疫治疗反应

Distinct tumor immune microenvironmental landscapes drive divergent immunotherapy responses in glioblastoma.

GBM 包含 3 种功能性 TIME 亚型，其血管-免疫景观存在差异，需要亚型特异性的治疗策略。

面向胶质母细胞瘤治疗的下一代 CAR-T 细胞工程改造：受体设计、抗原靶向与治疗持久性创新综述

Engineering next-generation CAR-T cells for glioblastoma treatment: a review of innovations in receptor design, antigen targeting, and therapeutic per

癌胎抗原作为嵌合抗原受体 (CAR)-T 细胞免疫治疗的新兴靶点：机遇与挑战

Oncofetal antigens as emerging targets in chimeric antigen receptor (CAR)-T cell-based immunotherapies: opportunities and challenges.

中枢神经系统肿瘤中的神经炎症

Neuroinflammation in Central Nervous System Tumors.